Impact of "killer immunoglobulin-like receptor/ligand" genotypes on outcome following surgery among patients with colorectal cancer: Activating KIRs are associated with long-term disease free survival

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Beksac, Kemal ^a   Beksac, Meral ^b   Dalva, Klara ^b   Karaagaoglu, Ergun ^a   Tirnaksiz, M Bulent ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; HLA B ANTIGEN; HLA C ANTIGEN; HLA-BW4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KIR2DL1 PROTEIN, HUMAN; KIR2DS2 PROTEIN, HUMAN; KIR2DS3 PROTEIN, HUMAN; KIR3DL1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA EXTRACTION; DNA ISOLATION; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TUMOR LOCALIZATION; AGED; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, KIR; RECEPTORS, KIR2DL1; RECEPTORS, KIR3DL1; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84941309407     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132526     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi: 10. 3322/caac.21166 PMID: 23335087
2. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, et al. (2013) Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 10: e1001453. doi: 10.1371/journal.pmed.1001453 PMID: 23700391
3. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425. PMID: 15467030
4. Pita-Fernandez S, Alhayek-Ai M, Gonzalez-Martin C, Lopez-Calvino B, Seoane-Pillado T, et al. (2014) Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol.
5. Singh K, Ohlan A, Pham VH, Balasubramaniyan R, Varshney S, et al. (2013) Nanostructured graphene/Fe(3)O(4) incorporated polyaniline as a high performance shield against electromagnetic pollution. Nanoscale 5: 2411-2420. doi: 10.1039/c3nr33962a PMID: 23400248
6. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28: 4531-4538. doi: 10.1200/JCO.2009.27. 2146 PMID: 20516428
7. Salama P, Platell C (2008) Host response to colorectal cancer. ANZ J Surg 78: 745-753. doi: 10.1111/j.1445-2197.2008.04642.x PMID: 18844901
8. Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, et al. (2003) Killer-cell immunoglobulinlike receptor (KIR) nomenclature report, 2002. Hum Immunol 64: 648-654. PMID: 12770798
9. Faure M, Long EO (2002) KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol 168: 6208-6214. PMID: 12055234
10. Middleton D, Gonzelez F (2010) The extensive polymorphism of KIR genes. Immunology 129: 8-19. doi: 10.1111/j.1365-2567.2009.03208.x PMID: 20028428
11. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, et al. (2005) Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54: 172-178. PMID: 15248031
12. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, et al. (2005) Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 201: 1069-1075. PMID: 15809352
13. Wisniewski A, Jankowska R, Passowicz-Muszynska E, Wisniewska E, Majorczyk E, et al. (2012) KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Hum Immunol 73: 927-931. doi: 10.1016/j.humimm.2012.07.323 PMID: 22836042
14. Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, et al. (2012) Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 1: 1104-1110. PMID: 23170258
15. Lopez-Vazquez A, Rodrigo L, Martinez-Borra J, Perez R, Rodriguez M, et al. (2005) Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 192: 162-165. PMID: 15942906
16. Besson C, Roetynck S, Williams F, Orsi L, Amiel C, et al. (2007) Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study. PLoS One 2: e406. PMID: 17476328
17. Bonagura VR, Du Z, Ashouri E, Luo L, Hatam LJ, et al. (2010) Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Hum Immunol 71: 212-219. doi: 10.1016/j.humimm.2009.10.009 PMID: 19861144
18. Middleton D, Vilchez JR, Cabrera T, Meenagh A, Williams F, et al. (2007) Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. Tissue Antigens 69: 220-226. PMID: 17493145
19. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, et al. (2010) Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 71: 976-981. doi: 10.1016/j.humimm.2010.06.019 PMID: 20600442
20. De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, et al. (2014) Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One 9: e84940. doi: 10.1371/journal.pone.0084940 PMID: 24497922 21. (1990) NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450. PMID: 2202842
21. Beksac M, Dalva K (2012) Role of killer immunoglobulin-like receptor and ligand matching in donor selection. Bone Marrow Res 2012: 271695. doi: 10.1155/2012/271695 PMID: 23193479
22. Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, et al. (2005) Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 42: 541-546. PMID: 15607811
23. Verheyden S, Schots R, Duquet W, Demanet C (2005) A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19: 1446-1451. PMID: 15973456
24. Babor F, Manser AR, Fischer JC, Scherenschlich N, Enczmann J, et al. (2014) The KIR ligand C2 is associated with increased susceptibility to childhood acute lymphoblastic leukemia and confers an elevated risk for late relapse. Blood 124: 2248-2251. doi: 10.1182/blood-2014-05-572065 PMID: 25163702
25. Owen JA, Punt J, Stranford SA, Jones PP (2013) Effector Responses: Cell-and Antibody-Mediated Immunity. In: Owen JA, Punt J, Stranford SA, editors. Kuby Immunology 7th ed. New York: W.H. Freeman. pp. 427-444.
26. Dorak MT (2007) Role of natural killer cells and killer immunoglobulin-like receptor polymorphisms: association of HLA and KIRs. Methods Mol Med 134: 123-144. PMID: 17666748
27. Yamazaki H, Yoshioka Y, Inoue T, Tanaka E, Nishikubo M, et al. (2002) Changes in natural killer cell activity by external radiotherapy and/or brachytherapy. Oncol Rep 9: 359-363. PMID: 11836608
28. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N (2008) Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol 15: 2388-2394. doi: 10.1245/s10434-008-0015-y PMID: 18622647